Several groups have characterized the pharmacology of ␣ 4 -or ␣ 6 ␤ 3 ␦-containing GABA A receptors expressed in different cell systems. We have previously demonstrated that the pharmacological profiles of a series of GABA A receptor agonists are highly dependent on the ␣ subunit and little on the ␤ and ␥ subunits, so to further understand the contribution of the different subunits in the GABA A receptor complex, we characterized a series of full agonists, partial agonists, and antagonists at ␣ 4 ␤ 3 , ␣ 4 ␤ 3 ␦, and ␣ 6 ␤ 3 ␦ receptors expressed in Xenopus oocytes. Little or no difference was seen when the compounds were compared at ␣␤-and ␣␤␦-containing receptors, whereas a significant reduction in both potency and relative efficacy was observed compared with ␣␤␥-containing receptors described in the literature. These data clearly confirm that the presence of the ␦ subunit in heterotrimeric receptors is a strong determinant of the increased pharmacological activity of compounds with agonist activity. The very similar agonist pharmacology of ␣␤-and ␣␤␦-containing receptors, which is significantly different from that of ␣␤␥-containing receptors, shows that whereas the presence of a ␥ subunit impairs the response to an agonist stimulation of the ␣␤ receptor complex, the ␦ subunit does not affect this in any way. Taken together, these data are well in line with the idea that ␣ 4 ␤ 3 ␦ may contribute to the pharmacological action of exogenously applied agonists and may explain why systemically active compounds such as gaboxadol and muscimol in vivo appear to act as selective extrasynaptic GABA A agonists.
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The major inhibitory neurotransmitter within the mammalian brain, GABA, mediates its fast transmission via the GABA A receptors. These ligand-gated ion channels assume a pentameric structure formed by coassembly of subunits from seven different classes (␣ 1-6 , ␤ 1-3 , ␥ 1-3 , ␦, ⑀, , and 1-3 ). Most native GABA A receptors are composed of two ␣, two ␤, and a ␥, ␦, or ⑀ subunit (for a recent review, see Sieghart and Sperk, 2002) . During the last decade, it has become increasingly evident that the subcellular localization of these receptors may be of crucial importance to the functional consequences of receptor activation. Thus, in addition to the synaptically located GABA A receptors, which are usually constituted by ␣␤␥ subunits, ␣␤␦-containing receptors may be selectively targeted to peri-or extrasynaptic sites (Stell et al., 2003; Wei et al., 2003) . It is generally agreed that the physiological role of these extrasynaptic receptors is to respond to synaptic spillover, thereby acting as sensors for extracellular GABA (Brickley et al., 2001) . Whereas receptors implicated in the direct synaptic transmission mediate phasic inhibitory signals, extrasynaptic receptors mediate tonic currents, which are thought to play a major role in refinement of the neuronal firing pattern (Brickley et al., 2001; Mody, 2001) .
Much of the current knowledge about the existence of extrasynaptic receptors originates from immunocytochemical studies combined with high-resolution electron microscopy. These studies have revealed that the subunit composition of synaptically located GABA A receptors may be distinctly different from that of extrasynaptic receptors. One of the most clear-cut examples is the ␣ 6 ␤␦ subtype, which is exclusively present at extrasynaptic sites in cerebellar granule cells, whereas the synaptically located receptor subtypes in these cells are dominated by ␣ 1 ␤␥ 2 and ␣ 1 ␣ 6 ␤␥ 2 subunits (Nusser et al., 1998) . Studies in transgenic mice, in which the expression of the ␣ 6 subunit has been obliterated, have demonstrated a post-translational loss of ␦ subunit protein in the cerebellum (Jones et al., 1997; Nusser et al., 1999; Brickley et al., 2001) . A similar subunit partnership has been suggested between ␣ 4 and ␦ subunits (Sur et al., 1999; Peng et al., 2002) . It has been speculated whether the cerebral homolog of ␣ 6 , the ␣ 4 subunit, is also located preferentially at extrasynaptic locations. This seems reasonable because both ␣ subunits render the receptor complexes insensitive toward benzodiazepines and because they exhibit complementary regional expression (cerebrum versus cerebellum) (Sieghart and Sperk, 2002) . Indeed, Sun et al. (2004) have recently demonstrated that ␣ 4 is located extrasynaptically in hippocampus.
Functional studies have shown that the extrasynaptic receptors act as low conductance channels (Bai et al., 2001 ). However, importantly, the potency of GABA is relatively high and the level and speed of desensitization are very small (Saxena and Macdonald, 1994) . A series of functional studies have all suggested that the main site of action for the GABA A receptor agonist gaboxadol may be the extrasynaptically located receptors. Expression of ␣ 4 ␤ 3 ␦-containing receptors and subsequent electrophysiological or biochemical characterization have shown that gaboxadol possesses both high potency and efficacy at these receptors (Adkins et al., 2001; Brown et al., 2002) . In tissue sections of rats, no synergistic interactions with benzodiazepines (mediating their effects via the synaptically located ␣ 1 -containing receptors) are seen (Storustovu and Ebert, 2003) . In addition, Liang et al. (2004) have shown that gaboxadol activates tonic currents elicited by extrasynaptic receptors in hippocampi of rats. It therefore seems very plausible that extrasynaptic receptors may be the main target for gaboxadol.
To further understand the mechanism of action of gaboxadol and to attempt to address what drives this previously unpredicted functional selectivity of gaboxadol, we have conducted the present study. We have expressed ␣ 4 ␤ 3 ␦ receptors in Xenopus oocytes and extended the findings by Adkins et al. (2001) and Brown et al. (2002) with thorough characterization of a broad spectrum of agonists, which in ␣ 1-6 ␤ x ␥ 2 receptors expressed in Xenopus oocytes have been found to behave as full and partial agonists (Ebert et al., 1994 (Ebert et al., , 1997 (Ebert et al., , 2001 . These compounds include, in addition to GABA, muscimol, isoguvacine, gaboxadol, piperidine-4-sulfonic acid (P4S), imidazole-4-acetic acid (IAA) and 5-(4-piperidyl)-3-isothiazolol (thio-4-PIOL). Furthermore, we have investigated the interaction of the same agonists with the cerebellar equivalent of ␦-containing GABA A receptors, namely the receptor subtype composed of ␣ 6 ␤ 3 ␦ subunits, to determine whether the altered pharmacology could be ascribed to the presence of the ␣ 4 or the ␦ subunit.
Materials and Methods
cRNA Preparation. Cloning and sequencing of cDNAs encoding human ␣ 4 , ␣ 6 , ␤ 3 , and ␦ GABA A receptor subunit proteins have been described elsewhere (Hadingham et al., 1993 (Hadingham et al., , 1996 Wafford et al., 1996; Thompson et al., 1997) . The cDNAs were engineered into a pcDNAI/Amp (␣ 4 , ␤ 3 , and ␦) or a pCDM8 (␣ 6 ) vector (Invitrogen, San Diego, CA). DNA was a kind gift from Dr. Paul Whiting, Merck Sharp and Dohme, Terlings Park, Harlow, UK. Large-scale cDNA preparation and purification were undertaken using a QIAGEN Plasmid Maxi kit (QIAGEN GmbH, Hilden, Germany). Plasmids were linearized using HpaI, XbaI, and NotI restriction enzymes for ␣ 4 /␦, ␤ 3 , and ␣ 6 cDNAs, respectively, and transcribed and capped in vitro (mMESSAGE mMACHINE T7 kit; Ambion, Austin, TX). The RNAs were precipitated with LiCl, redissolved in sterile RNase-free water, and stored at Ϫ80°C. cRNA was kindly supplied by Jan Egebjerg and Lene Heding, Department of Molecular Genetics, H. Lundbeck A/S, Valby, Denmark.
Oocyte Isolation and Injection. An adult female Xenopus laevis was anesthetized by immersion in a 0.4% (w/v) 3-aminobenzoic acid ethyl ester solution (Sigma Chemical, St. Louis, MO) for 15 to 20 min. Through an incision in the abdominal wall two to three ovarian lobes were removed, and stage V and VI oocytes were manually defolliculated with watchmaker's fine forceps. After mild collagenase treatment [type IA (Sigma), 0.5 mg/ml for 6 min] to remove remaining follicle cells, each oocyte was injected with various combinations of ␣ 4 -, ␤ 3 -, and ␦-encoding cRNA (␣ 4 and ␦: 32.2 ng/oocyte; ␤ 3 : 3.2 ng/oocyte). Oocytes were incubated for at least 4 days in modified Barth's saline [88 mM NaCl, 1 mM KCl, 15 mM HEPES, 2.4 mM NaHCO 3 , 0.41 mM CaCl 2 , 0.82 mM MgSO 4 , and 0.3 mM Ca(NO 3 ) 2 ] supplemented with 2 mM sodium pyruvate, 0.1 U/l penicillin, and 0.1 g/l streptomycin and filtered through nitrocellulose.
Two-Electrode Voltage Clamping. Oocytes were placed in a 60-l bath and perfused with Ringer's solution (115 mM NaCl, 2.5 mM KCl, 10 mM HEPES, 1.8 mM CaCl 2 , and 0.1 mM MgCl 2 , pH 7.5). Cells were impaled with agar-plugged 0.5 to 1 M⍀ electrodes containing 3 M KCl and voltage-clamped at Ϫ70 mV by a GeneClamp 500B amplifier (Molecular Devices Corporation, Sunnyvale, CA) with a gain setting of ϫ1 or ϫ10. The cells were continuously perfused with Ringer's buffer at 4 to 6 ml/min, and the drugs were applied in the perfusate. Agonist-containing solutions were applied until the peak of the response was observed, usually after 30 s or less. A 6-to 10-min washout period between agonist applications was allowed to minimize desensitization. To ensure complete binding, antagonists were preapplied alone for 1 min before their coapplication with GABA.
Data Analysis. Agonist concentration-response curves obtained from Xenopus oocytes were fitted by use of the nonlinear, leastsquares fitting program, GraFit 5.0.10 (Erithacus Software, Horley, Surrey, UK). Data series from each individual oocyte were normalized with respect to the maximum GABA current, GABA I max , elicited from that particular cell and fitted to eq. 1:
where E max is the maximum response, [L] is the concentration of the ligand, EC 50 is the concentration of the ligand eliciting 50% of the maximal response, and n H is the slope factor. The competitive GABA A receptor antagonists were characterized with respect to their ability to shift a GABA concentration-response curve rightward when present in a fixed concentration. K i values for these antagonists were derived from coanalysis of data obtained from each individual oocyte in the absence and presence of antagonist by use of the Waud equation:
where [I] is the (fixed) antagonist concentration. Geometric mean values of the K i values were calculated. Concentration-inhibition curves for Zn 2ϩ and La 3ϩ were performed by application of increasing concentrations of the cations in the presence of a fixed concentration of GABA corresponding to the exact EC 50 value determined for each individual cell before the concentration-inhibition experiment. Data were normalized with respect to the GABA EC 50 response and fitted to eq. 3:
where IC 50 is the inhibitor concentration yielding 50% inhibition of the GABA EC 50 response and background is an arbitrary constant. Experiments were performed on at least four different oocytes stemming from at least two different oocyte batches. When a putative two-site behavior was in question, the data were fitted to eq. 4:
With an F test comparing the 2 values obtained from the two fits (using eq. 3 or 4, respectively) and the degrees of freedom in each, we statistically tested whether the two-site equation fitted the data significantly better than the one-site equation.
Drugs and Solutions. Stock solutions of GABA (1 M) were made in double-distilled water and stored in aliquots at Ϫ20°C. The remaining compounds were dissolved freshly in double-distilled water at a concentration of 10 to 100 mM. Final drug solutions were made by dilution in Ringer's solution. All chemicals were purchased from conventional commercial sources except for 5-(4-piperidyl)-3-isoxazolol (4-PIOL) and thio-4-PIOL, which were kind gifts from Bente Frølund, Department of Medicinal Chemistry, The Danish University of Pharmaceutical Sciences, Copenhagen, Denmark.
Results
␣ 4 ␤ 3 -and ␣ 4 ␤ 3 ␦-Expressing Xenopus Oocytes. Various combinations of GABA A receptor ␣ 4 , ␤ 3 , and ␦ subunits encoding cRNAs were injected in Xenopus oocytes. Whereas injection of ␣ 4 ␤ 3 and ␣ 4 ␤ 3 ␦ subunit combinations gave rise to functional receptors with maximal GABA currents, GABA I max , of 314 Ϯ 48 (mean Ϯ S.E.M.) and 103 Ϯ 29 nA, respectively, no GABA-elicited currents could be measured in ␤ 3 ␦-and ␣ 4 ␦-injected oocytes.
Because the ␦ subunit is notoriously difficult to coexpress in recombinant systems, it can be questioned whether or not all the expressed receptor complexes in oocytes injected with ␣ 4 ␤ 3 ␦ encoding cRNA really do contain the ␦ subunit. In an attempt to increase the fraction of ␦-containing receptor complexes as much as possible, a 10-fold excess of ␦-encoding cRNA was injected as previously reported by Sundström-Poromaa et al. (2002) . Furthermore, we strove to find a pharmacological tool capable of discriminating between the two different assemblies of subunits, thus giving a means of assessing the homogeneity of the receptor population. The polyvalent cations Zn 2ϩ and La 3ϩ are well established negative allosteric modulators of certain GABA A receptor subunit assemblies, whereas other subunit combinations seem to be less sensitive to these cations. Zn 2ϩ has been reported to inhibit recombinant ␣ 1 ␤ x receptors, whereas their ␥ 2 -containing counterparts are virtually insensitive to inhibition (e.g., Smart et al., 1991; Wooltorton et al., 1997; Nagaya and Macdonald, 2001 ). In addition, Brown et al. (2002) have recently demonstrated a pronounced difference in the sensitivity toward La 3ϩ between ␣ 4 ␤ 3 ␥ 2S -and ␣ 4 ␤ 3 ␦-containing receptors stably expressed in L(tk) cells and a less significant difference between the same constructs toward Zn 2ϩ , with ␣ 4 ␤ 3 ␥ 2S being the most sensitive.
Therefore, concentration-inhibition studies were performed by application of increasing concentrations of the cations in the presence of an EC 50 GABA concentration (determined for each individual cell). Data were fitted to eq. 3.
In our system, the ␣ 4 ␤ 3 ␦ combination proved to be sensitive to La 3ϩ with an IC 50 value of 5.7 M, whereas the ␦-deficient receptors were practically insensitive (Fig. 1, left panel) . However, because even high concentrations of La 3ϩ could only bring about approximately 50% inhibition of the GABA EC 50 responses at ␣ 4 ␤ 3 ␦ receptors and because the degree of inhibition of the ␣ 4 ␤ 3 receptor complexes turned out to be variable, La 3ϩ would to all appearances not be the most suitable tool for discrimination between ␦-deficient and ␦-containing receptor complexes. Therefore, similar experiments were carried out using Zn 2ϩ instead. As illustrated in Fig. 1 (right panel) and Table 1 , Zn 2ϩ is a potent inhibitor of GABA responses at ␣ 4 ␤ 3 -containing receptors (IC 50 ϭ 62 nM), whereas ␣ 4 ␤ 3 ␦-containing receptors are 100-fold less sensitive (IC 50 ϭ 5.3 M). This finding demonstrates that the ␦ subunit is in fact incorporated into functional receptor complexes expressed at the cell surface.
Thus, as seen from Fig. 1 , if coapplication of GABA and 0.1 Table 1 . Agonists at ␦-Containing GABA A Receptors M Zn 2ϩ to ␣ 4 ␤ 3 ␦ receptors yields a response of approximately 80% of the EC 50 response or less, the receptor population presumably will contain a considerable fraction of ␣ 4 ␤ 3 receptors. Now having an efficient means of assessing the receptor population purity, we proceeded with agonist concentration-responses curves.
A wide variety of agonists, which have proven to be full and partial agonists at ␣ 1-6 ␤ x ␥ 2S receptors (Ebert et al., 1994 (Ebert et al., , 1997 (Ebert et al., , 2001 , were tested at ␣ 4 ␤ 3 ␦-expressing oocytes. As seen from Fig. 2a and Table 2 , gaboxadol, isoguvacine, and muscimol appeared to elicit higher maximal responses than GABA, with gaboxadol being the most efficacious with an E max value of 215 Ϯ 10.6% compared with the 191 Ϯ 6.7 and 144 Ϯ 4.2% found for isoguvacine and muscimol, respectively. On the contrary, P4S and IAA behaved as partial agonists with maximal responses of about 65%. In addition, the low-efficacy partial agonists, thio-4-PIOL and 4-PIOL, were tested, with the former giving an E max value of 4.4 Ϯ 0.6%. For 4-PIOL, however, the agonist responses were so minute that they could not be adequately separated from the background noise. With EC 50 values in the low micromolar range, GABA and muscimol turned out to be 10-to 50-fold more potent than the remaining agonists (Table 2) .
To investigate whether the highly efficacious behavior of gaboxadol would be due to a ␦-specific receptor interaction, this agonist was tested at ␣ 4 ␤ 3 GABA A receptors. As reference compounds the full agonist GABA and the partial agonist P4S were chosen. Interestingly, these three compounds displayed the same potencies as at the ␣ 4 ␤ 3 ␦-containing receptors. In addition, no large discrepancies between relative Fig. 2 . a, concentration-response curves for a broad range of GABA A receptor agonists obtained in Xenopus oocytes expressing GABA A receptors composed of ␣ 4 ␤ 3 ␦ subunits. The inset depicts an enlarged excerpt of the lower part of the graph containing the partial agonist concentration-response curves. b, comparison of agonist curves for THIP, GABA, and P4S at GABA A receptors composed from ␣ 4 ␤ 3 ␦ and ␣ 4 ␤ 3 subunits. All data were normalized with respect to GABA I max and subsequently fitted to eq. 1. Derived parameters are seen in Table 2 . c, representative example of a trace recorded from a Xenopus oocyte expressing ␣ 4 ␤ 3 ␦ subunits. The horizontal bars indicate application of the gaboxadol or GABA concentration given above each bar.
Stó rustovu and Ebert
at ASPET Journals on July 11, 2017 jpet.aspetjournals.org Downloaded from efficacy levels of the agonists at the two different subunit combinations were found (Table 2) .
In an attempt to further address the functional differences between gaboxadol and GABA, GABA was coapplied with a fixed concentration of gaboxadol at ␣ 4 ␤ 3 ␦-containing receptors. As illustrated in Fig. 3 , GABA concentration dependently reduced the response to gaboxadol until the response corresponded to the maximum response to GABA. This reduction was not due to desensitization or down-regulation of receptors, because the response to gaboxadol after coapplication with GABA was similar to that before the coapplication (data not shown).
The potencies of the two standard competitive antagonists, bicuculline methochloride (BMC) and SR 95531 (gabazine), were established from ␣ 4 ␤ 3 ␦-expressing oocytes, using the ability of a fixed concentration of these compounds to cause a parallel, rightward shift of a GABA concentration-response curve. A representative example of such a shift is seen in Fig.  4 . Coanalysis of the concentration-response curves in the absence and presence of the antagonists (using eq. 2, see Materials and Methods) revealed K i values of 1.16 M and 95 nM for BMC and SR 95531, respectively (Table 3) . Likewise, the antagonist properties of the two very low efficacy partial agonists, 4-PIOL and thio-4-PIOL, were assessed by the same procedure, yielding K i values of 13.5 and 3.33 M, respectively (Table 3) .
␣ 6 ␤ 3 ␦-Expressing Xenopus Oocytes. To evaluate the agonist pharmacology at another major extrasynaptic receptor subtype, the cerebellar ␣ 6 ␤␦-containing GABA A receptors (Nusser et al., 1998; Sassoe-Pognetto et al., 2000) , Xenopus oocytes were injected with ␣ 6 ␤ 3 ␦-encoding cRNAs in a subunit ratio of 10:1:10. As for the ␣ 4 ␤ 3 ␦-containing receptors, the full incorporation of the ␦ subunit into the expressed receptors was a matter of some concern. Surprisingly, control experiments revealed that injection of ␦-deficient ␣ 6 ␤ 3 cRNAs did not give rise to formation of functional receptor complexes sensitive to GABA or other agonists, whereas robust expression was obtained with ␣ 6 ␤ 3 ␦-encoding cRNAs Fig. 4 . Example of a rightward parallel shift of a GABA concentrationresponse curve obtained with 10 M bicuculline in Xenopus oocytes expressing GABA A receptors composed of ␣ 4 ␤ 3 ␦ subunits. In the absence of the antagonist, an EC 50 value of 2.7 M was obtained (F). In the presence of 10 M bicuculline the EC 50 was shifted approximately 10-fold to 32 M (E). Data were fitted to eq. 2. Fig. 3 . a, concentration-response curves for GABA and gaboxadol in Xenopus oocytes expressing GABA A receptors composed of ␣ 4 ␤ 3 ␦ subunits. b, at ␣ 4 ␤ 3 ␦-containing receptors, GABA acts as a partial agonist. With increasing concentrations of GABA, the response to a fixed concentration of gaboxadol (300 M) is suppressed approximately to the relative efficacy level of GABA alone (n ϭ 4). All data were normalized with respect to GABA I max and subsequently fitted to the eq. 3. (GABA I max ϭ 304 Ϯ 48 nA, mean Ϯ S.E.M.). Although in contrast to findings from other oocyte laboratories (e.g., Thompson et al., 1997; Wallner et al., 2003) , the lack of ␣ 6 ␤ 3 expression might indicate that formation of this receptor by-product in ␣ 6 ␤ 3 ␦-injected oocytes is not a crucial problem. However, to prove the presence of ␦ subunits in ␣ 6 ␤ 3 ␦-expressing oocytes, a series of zinc experiments, performed as described previously, were conducted. As seen from the concentration-inhibition curve depicted in Fig. 5 , left panel, and the slope factor, n H , in Table 4 , the course of the curve was not as steep as that seen at ␣ 4 ␤ 3 ␦ receptors. In fact, for all the oocytes, a more shallow curve was apparent, suggesting two distinct binding sites. However, when the goodness of the fits obtained from a one-site and a two-site equation were compared by an F test, the two-site equation was significantly better than the one-site equation only in two instances. A concentration-inhibition curve for one of these cells is seen in Fig. 5 , right panel (p Ͻ 0.005 when a two-site fit was compared with a one-site fit). Interaction with the primary site yielded an IC 50 value of 2.6 M (resolved by use of eq. 4) and a secondary low-affinity site (IC 50 ϭ 240 M) could also be identified. However, because of the high variability in the appearance of the two sites, we will refrain from speculating about its significance, which at the current time remains enigmatic. When fitting the data to the traditional one-site equation (eq. 3), the IC 50 value obtained from the ␣ 6 ␤ 3 ␦-expressing oocytes (8.7 M) was in the same range as that derived from ␣ 4 ␤ 3 ␦-expressing oocytes (5.3 M) and, furthermore, in agreement with findings of Thompson et al. (1997) who in similar experiments found IC 50 values of 0.42 and 8.6 M in ␣ 6 ␤ 3 -and ␣ 6 ␤ 3 ␦-expressing oocytes. Conclusively, these data suggest that the ␦ subunit is indeed present along with ␣ 6 and ␤ 3 in the expressed receptor complexes.
Agonists at ␦-Containing
Next, a series of concentration-response studies were performed with GABA, gaboxadol, isoguvacine, muscimol, IAA, and P4S ( Fig. 6 ; Table 5 ). As observed at ␣ 4 ␤ 3 ␦-containing receptors, gaboxadol, isoguvacine, and muscimol proved to elicit a higher maximal response than GABA, whereas IAA and P4S behaved as partial agonists. All compounds interacted more potently with ␣ 6 ␤ 3 ␦ than with ␣ 4 ␤ 3 ␦. With respect to the E max values, a further polarization of the efficacy levels was observed in that gaboxadol, isoguvacine, and muscimol interacted more efficaciously with the former receptor subtype than with the latter whereas the reverse was the case for the partial agonists.
Discussion
We have suggested previously that the GABA A receptor agonist, gaboxadol, and the allosteric benzodiazepines site agonists, including the standard 1,4-benzodiazepines as well as the more recent compounds with nonbenzodiazepine structures such as zaleplon, zolpidem, zopiclone and indiplon, in addition to binding to different recognition sites also interact with two distinctly different receptor populations in the mammalian brain. According to our interpretation of data generated from the rat cortical wedge preparation and from rotarod studies in the rat, benzodiazepines primarily interact with synaptically located ␣ 1 ␤ 2/3 ␥ 2 -containing receptors whereas gaboxadol's main target seems to be extrasynaptic ␣ 4 ␤ 3 ␦ receptors (Ebert et al., 2002; Storustovu and Ebert, 2003; Voss et al., 2003) . To shed further light on gaboxadol's apparent functional selectivity for GABA A receptors composed of ␣ 4 ␤ 3 ␦ subunits, we expressed this subunit combination in Xenopus oocytes. 5 . Zinc concentration-inhibition curves obtained from Xenopus oocytes expressing GABA A receptors composed from ␣ 6 ␤ 3 ␦ subunits (n ϭ 5). Data were normalized with respect to the GABA EC 50 response and fitted to eq. 3. Fitting results are presented in Table 4 . Because the ␦ subunit has proven difficult to coexpress, our attention was focused on demonstrating that this subunit was actually incorporated into the expressed receptor complexes at the cell surface. Initially, in an attempt to elucidate potential differences in the agonist pharmacology of the ␦-deficient versus ␦-containing receptor complexes, potencies and relative efficacies for gaboxadol, GABA, and P4S were established from the two different receptor constructs. However, no differences in the potencies and only minor differences in the relative efficacies were found. This finding suggests either that the ␦ subunit is not successfully incorporated or that the ␦ subunit does not alter the agonist responsiveness. To clarify whether or not the former possibility was the case, we investigated the sensitivity of the two subunit combinations toward the negative modulators, Zn 2ϩ and La 3ϩ , and found significant differences in the Zn 2ϩ sensitivity between ␣ 4 ␤ 3 (IC 50 ϭ 62 nM)-and ␣ 4 ␤ 3 ␦ (IC 50 ϭ 5.3 M)-containing receptors. These findings are in perfect agreement with results from analogous studies in ␣ 6 ␤ 3 -and ␣ 6 ␤ 3 ␦-containing receptors expressed in Xenopus oocytes . Here, Thompson et al. found no difference between GABA potencies at the two different subunit assemblies, whereas a 100-fold difference in Zn 2ϩ sensitivities was observed. Thus, in contrast to ␥ 2 -containing receptor complexes (for which the presence of a ␥ subunit renders the receptor complex less sensitive to agonists (for a recent review, see Sieghart and Sperk, 2002) , the incorporation of a ␦ subunit does not seem to lead to alteration of the agonist-gating properties of the receptor complex.
At ␣ 6 ␤ 3 ␦-containing receptors, gaboxadol, muscimol, and isoguvacine showed even higher relative efficacy and potency levels than at ␣ 4 ␤ 3 ␦-containing receptors. The expression of ␣ 6 is confined to granule cells of the cerebellum where it assembles with ␤ 2/3 and ␦ subunits (Jones et al., 1997; Jechlinger et al., 1998; Nusser et al., 1999; Sassoe-Pognetto et al., 2000) to form receptor complexes almost exclusively found at extrasynaptic locations (Nusser et al., 1999; Sassoe-Pognetto et al., 2000) . Because cerebellum plays a key role in the refinement of motor action, an involvement of ␣ 6 -containing receptors in motor coordination could be expected. However, studies in transgenic mice, in which the expression of ␣ 6 has been obliterated, have not revealed any major phenotypic deficits. Thus, these ␣ 6 knockout mice seem to breed and develop normally (Homanics et al., 1997; Jones et al., 1997) and exhibit no difference in motor performance from their wild-type littermates (Jones et al., 1997) . Thus, at present, the functional importance of ␣ 6 ␤ 2/3 ␦-containing GABA A receptors remains enigmatic.
In Fig. 7 , the concentration-response relationship for gaboxadol at ␣ 4 ␤ 3 ␦-and ␣ 6 ␤ 3 ␦-containing receptors is compared with those of ␣ 1-6 ␤ 3 ␥ 2S -containing GABA A receptors. Fig. 6 . Concentration-response curves for a broad range of GABA A receptor agonists obtained in Xenopus oocytes expressing GABA A receptors composed of ␣ 6 ␤ 3 ␦ subunits. All data were normalized with respect to GABA I max and subsequently fitted to the eq. 1. Derived parameters are seen in Table 5 . (Ebert et al., 2001) . The gray bar enclosed by dashed lines indicates the therapeutically relevant concentration area (Madsen et al., 1983) .
As seen from the figure, gaboxadol interacts much more potently and efficaciously with the ␣ 4/6 ␤ 3 ␦-containing receptors than with any of the ␥ 2 -containing receptors. Curiously, the highly efficacious behavior of gaboxadol at the former subunit combinations could seem to be a ␦-specific property, because this behavior is not found at ␣ 4 ␤ 3 ␥ 2S -expressing oocytes or at any other of the ␥ 2 -containing receptors. On the other hand, the high relative efficacy level is also found at the ␦-deficient ␣ 4 ␤ 3 receptors, indicating that the ␥ 2 subunit would be the one that renders the receptors "resistant" to relative efficacy levels higher than that of GABA. This points to the fact the ␦-and ␥ 2 -containing receptors possess dissimilar gating properties, which is in line with the observation that the former receptors are insensitive toward BZD modulation whereas the ␥ subunit confers BZD sensitivity to ␣ 1-3,5 ␤␥ receptor complexes. In previous publications on ␣ 4 ␤ 3 ␦-containing receptors, the activity of gaboxadol was termed "superagonism" (Adkins et al., 2001; Brown et al., 2002) . However, as demonstrated in Fig. 3 , the relative increase in the maximal response of gaboxadol (relative to GABA) is primarily a consequence of a reduced maximal response to GABA, making this endogenous ligand a partial agonist at ␣ 4 ␤ 3 ␦-containing receptors. Thus, GABA, as predicted by the concept of partial agonism, is able to suppress the response to gaboxadol until a level of response corresponding to that of GABA is obtained. The mechanism underlying this partial agonist activity of GABA still remains to be addressed.
In conclusion, the present oocyte data suggest that gaboxadol interacts potently and efficaciously with ␣ 4 ␤ 3 -, ␣ 4 ␤ 3 ␦-, and ␣ 6 ␤ 3 ␦-containing receptors, for all of which a predominantly extrasynaptic localization has been proposed (Nusser et al., 1998; Sun et al., 2004) . Furthermore, since clinical observations (e.g., Faulhaber et al., 1997) have indicated that a single p.o. dose of 10 to 15 mg of gaboxadol modulates sleep, and plasma concentration at these doses lie within 0.5 to 2 M (Madsen et al., 1983 ) (shown by a gray bar in Fig. 7) , plasma concentrations relevant for the activation of extra synaptic GABA A receptors are obtained in humans. It is not currently known whether gaboxadol is accumulated in the central nervous system after a single exposure. It may therefore be possible that a higher concentration of gaboxadol in the central nervous system than that in the plasma may be present. However, previous studies with gaboxadol in slices from rodents (e.g., Shen et al., 2005) have used concentrations in the low micromolar range, indicating that effects are obtained within this concentration range. In this low micromolar concentration range, gaboxadol activates only ␣ 4 ␤ 3 ␦-and ␣ 6 ␤ 3 ␦-containing receptors. These data are therefore in agreement with our previously published hypothesis that these extrasynaptically located and BZD-insensitive receptors are the primary sites of action of gaboxadol and underline the hypothesis that BZD site agonists and the GABA A receptor agonist, gaboxadol, act at two different receptor populations. This may also explain why no cross-sensitization between gaboxadol and zolpidem was observed in a cross-tolerance study using the rotarod model in the rat (Voss et al., 2003) . Similarly, lorazepam-trained rats and baboons have been shown not to occasion drug-lever responding in a food-maintained two-lever drug versus no-drug discrimination procedure when exposed to gaboxadol (Ator and Griffiths, 1986 ). In a similar experimental paradigm, using muscimol-trained rats, administration of gaboxadol produced full substitution for muscimol, whereas diazepam failed to produce full substitution (Jones and Balster, 1998) . Analogously, in zolpidem-trained squirrel monkeys, full substitution was observed in at least half of the subjects studied after triazolam, lorazepam, midazolam, diazepam, and chlordiazepoxide (but not oxazepam) administration, in contrast to findings with i.a. muscimol, baclofen, and buspirone, which did not evoke substantial substitution (Rowlett et al., 1999) . Hence, both rodents and primates do not appear to be able to distinguish the various benzodiazepine site agonists from each other, regardless of chemical structure, whereas drugs that bind to other (non-BZD) sites (i.e., gaboxadol and muscimol) are surprisingly discernible from the benzodiazepines, thus demonstrating the distinct molecular mechanisms of action of the two compound classes.
Taken together, several lines of evidence obtained from in vivo and in vitro studies have emphasized that gaboxadol seems to interact with a GABA A receptor population, which is distinctly different from that targeted by the benzodiazepines. The present data add further evidence to our previous published hypothesis that a specific interaction with extrasynaptically located GABA A receptors underlies the novel pharmacological profile of gaboxadol.
